{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:47:14Z","timestamp":1790858834403,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in Dystrophin, one of the largest proteins in the mammalian body, are causative for a severe form of muscle disease, Duchenne Muscular Dystrophy (DMD), affecting not only skeletal muscle, but also the heart. In particular, exons 45\u201352 constitute a hotspot for <jats:italic>DMD<\/jats:italic> mutations. A variety of molecular therapies have been developed, comprising vectors encoding micro- and minidystrophins as well as utrophin, a protein with partially overlapping functions. With the advent of the CRISPR-Cas9-nuclease, genome editing offers a novel option of correction of the disease-cuasing mutations. Full restoration of the healthy gene by homology directed repair is a rare event. However, non-homologous end-joining (NHEJ) may restore the reading frame by causing exon excision. This approach has first been demonstrated in mice and then translated to large animals (dogs, pigs). This review discusses the potential opportunities and limitations of genome editing in DMD, including the generation of appropriate animal models as well as new developments in genome editing tools.<\/jats:p>","DOI":"10.1038\/s41434-021-00222-4","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T17:04:29Z","timestamp":1612285469000},"page":"542-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Genome editing for Duchenne muscular dystrophy: a glimpse of the future?"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-1218","authenticated-orcid":false,"given":"Christian","family":"Kupatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie C.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"222_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17:445\u201355.","journal-title":"Lancet Neurol"},{"key":"222_CR2","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93:e1312\u201323.","journal-title":"Neurology"},{"key":"222_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JND-180341","volume":"6","author":"E Finanger","year":"2019","unstructured":"Finanger E, Vandenborne K, Finkel RS, Lee Sweeney H, Tennekoon G, Yum S, et al. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-\u03baB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2019;6:43\u201354.","journal-title":"J Neuromuscul Dis"},{"key":"222_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","volume":"30","author":"KR Wagner","year":"2020","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK, Campbell C, Guglieri M, Muntoni F, et al. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30:492\u2013502.","journal-title":"Neuromuscul Disord"},{"key":"222_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008","volume":"30","author":"L Servais","year":"2020","unstructured":"Servais L, Straathof CSM, Schara U, Klein A, Leinonen M, Hasham S, et al. Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2020;30:5\u201316.","journal-title":"Neuromuscul Disord"},{"key":"222_CR6","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1093\/hmg\/ddt352","volume":"22","author":"MG Morales","year":"2013","unstructured":"Morales MG, Gutierrez J, Cabello-Verrugio C, Cabrera D, Lipson KE, Goldschmeding R, et al. Reducing CTGF\/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Human Mol Genet. 2013;22:4938\u201351.","journal-title":"Human Mol Genet"},{"key":"222_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, D\u2019Amico A, Catteruccia M, Pane M, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:643\u20139.","journal-title":"Neuromuscul Disord"},{"key":"222_CR8","doi-asserted-by":"publisher","unstructured":"Rogers RG, Fournier M, Sanchez L, Ibrahim AG, Aminzadeh MA, Lewis MI, et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. JCI Insight. 2019;4. https:\/\/doi.org\/10.1172\/JCI.insight.125754.","DOI":"10.1172\/JCI.insight.125754"},{"key":"222_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","volume":"27","author":"R Xu","year":"2019","unstructured":"Xu R, Jia Y, Zygmunt DA, Martin PT. rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart. Mol Ther. 2019;27:636\u201349.","journal-title":"Mol Ther"},{"key":"222_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","volume":"15","author":"PB Shieh","year":"2018","unstructured":"Shieh PB. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy. Neurotherapeutics. 2018;15:840\u20138.","journal-title":"Neurotherapeutics"},{"key":"222_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nature Rev Neurol. 2019;15:373\u201386.","journal-title":"Nature Rev Neurol"},{"key":"222_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ana.20052","volume":"55","author":"MT Howard","year":"2004","unstructured":"Howard MT, Anderson CB, Fass U, Khatri S, Gesteland RF, Atkins JF, et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Annals Neurol. 2004;55:422\u20136.","journal-title":"Annals Neurol"},{"key":"222_CR13","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1111\/jcmm.15319","volume":"24","author":"J Berger","year":"2020","unstructured":"Berger J, Li M, Berger S, Meilak M, Rientjes J, Currie PD. Effect of Ataluren on dystrophin mutations. J Cell Mol Med. 2020;24:6680\u20139.","journal-title":"J Cell Mol Med"},{"key":"222_CR14","doi-asserted-by":"publisher","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B, B\u00f6nnemann C, Sampson J, Sweeney HL, et al. Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. PloS ONE. 2013;8:e81302.","journal-title":"PloS ONE"},{"key":"222_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50:477\u201387.","journal-title":"Muscle Nerve"},{"key":"222_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N. et al.Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.2017;390:1489\u201398.","journal-title":"Lancet."},{"key":"222_CR17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0960-8966(18)30325-0","volume":"28","author":"R Kong","year":"2018","unstructured":"Kong R, O\u2019Mara E, Luo X, Trifillis P, Werner C, McIntosh J. D22 - A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged \u22652 to <5 years with nonsense mutation Duchenne muscular dystrophy. Neuromuscular Disord. 2018;28:S12\u20133.","journal-title":"Neuromuscular Disord"},{"key":"222_CR18","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1056\/NEJMoa073108","volume":"357","author":"JC van Deutekom","year":"2007","unstructured":"van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local Dystrophin Restoration with Antisense Oligonucleotide PRO051. NEJM. 2007;357:2677\u201386.","journal-title":"NEJM"},{"key":"222_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637\u201347.","journal-title":"Ann Neurol"},{"key":"222_CR20","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","volume":"27","author":"L Echevarr\u00eda","year":"2018","unstructured":"Echevarr\u00eda L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Human Mol Genet. 2018;27:R163\u201372.","journal-title":"Human Mol Genet"},{"key":"222_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180\u20132.","journal-title":"Nature"},{"key":"222_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"SQ Harper","year":"2002","unstructured":"Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253\u201361.","journal-title":"Nat Med"},{"key":"222_CR23","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D, Systemic AAV. Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther: J Am Soc Gene Ther. 2018;26:2337\u201356.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"222_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1089\/hum.2011.017","volume":"23","author":"S Schinkel","year":"2012","unstructured":"Schinkel S, Bauer R, Bekeredjian R, Stucka R, Rutschow D, Lochm\u00fcller H, et al. Long-Term Preservation of Cardiac Structure and Function After Adeno-Associated Virus Serotype 9-Mediated Microdystrophin Gene Transfer in mdx Mice. Human Gene Ther. 2012;23:566\u201375.","journal-title":"Human Gene Ther"},{"key":"222_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/mt.2012.283","volume":"21","author":"JH Shin","year":"2013","unstructured":"Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, et al. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther. 2013;21:750\u20137.","journal-title":"Mol Ther"},{"key":"222_CR26","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989;244:1578\u201380.","journal-title":"Science"},{"key":"222_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nature Commun. 2017;8:16105.","journal-title":"Nature Commun"},{"key":"222_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Cell. 2014;159:440\u201355.","journal-title":"Cell"},{"key":"222_CR29","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.1254445","volume":"345","author":"C Long","year":"2014","unstructured":"Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA. Science. 2014;345:1184\u20138.","journal-title":"Science"},{"key":"222_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400\u20133.","journal-title":"Science"},{"key":"222_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407\u201311.","journal-title":"Science"},{"key":"222_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403\u20137.","journal-title":"Science"},{"key":"222_CR33","doi-asserted-by":"crossref","unstructured":"EL Refaey M, Xu L, Gao Y, Canan BD, Adesanya TA, Warner SC, et al. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. Circulation Res. 2017;121:923\u20139.","DOI":"10.1161\/CIRCRESAHA.117.310996"},{"key":"222_CR34","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1172\/JCI141777","volume":"130","author":"GL Shah","year":"2020","unstructured":"Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Investig. 2020;130:6656\u201367.","journal-title":"J Clin Investig"},{"key":"222_CR35","doi-asserted-by":"crossref","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362:86\u201391.","DOI":"10.1126\/science.aau1549"},{"key":"222_CR36","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1093\/hmg\/ddt287","volume":"22","author":"N Klymiuk","year":"2013","unstructured":"Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, et al. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Human Mol Genet. 2013;22:4368\u201382.","journal-title":"Human Mol Genet"},{"key":"222_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep33362","volume":"6","author":"T Fr\u00f6hlich","year":"2016","unstructured":"Fr\u00f6hlich T, Kemter E, Flenkenthaler F, Klymiuk N, Otte KA, Blutke A, et al. Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy. Scientific Rep. 2016;6:33362.","journal-title":"Scientific Rep"},{"key":"222_CR38","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.isci.2020.101516","volume":"23","author":"H Tamiyakul","year":"2020","unstructured":"Tamiyakul H, Kemter E, K\u00f6sters M, Ebner S, Blutke A, Klymiuk N, et al. Progressive Proteome Changes in the Myocardium of a Pig Model for Duchenne Muscular Dystrophy. iScience. 2020;23:101516.","journal-title":"iScience"},{"key":"222_CR39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1073\/pnas.1715940115","volume":"115","author":"H Matsunari","year":"2018","unstructured":"Matsunari H, Watanabe M, Nakano K, Enosawa S, Umeyama K, Uchikura A, et al. Modeling lethal X-linked genetic disorders in pigs with ensured fertility. Proc Natl Acad Sci. 2018;115:708\u201313.","journal-title":"Proc Natl Acad Sci"},{"key":"222_CR40","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1089\/hum.2008.009","volume":"19","author":"J Li","year":"2008","unstructured":"Li J, Sun W, Wang B, Xiao X, Liu XQ. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Human Gene Ther. 2008;19:958\u201364.","journal-title":"Human Gene Ther"},{"key":"222_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coviro.2014.07.008","volume":"8","author":"E Zinn","year":"2014","unstructured":"Zinn E, Vandenberghe LH. Adeno-associated virus: fit to serve. Curr Opin Virol. 2014;8:90\u20137.","journal-title":"Curr Opin Virol"},{"key":"222_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.cell.2015.08.007","volume":"162","author":"H Nishimasu","year":"2015","unstructured":"Nishimasu H, Cong L, Yan WX, Ran FA, Zetsche B, Li Y, et al. Crystal Structure of Staphylococcus aureus Cas9. Cell. 2015;162:1113\u201326.","journal-title":"Cell"},{"key":"222_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186\u2013191.","journal-title":"Nature"},{"key":"222_CR44","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1093\/nar\/gkv601","volume":"43","author":"DJ Truong","year":"2015","unstructured":"Truong DJ, Kuhner K, Kuhn R, Werfel S, Engelhardt S, Wurst W, et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 2015;43:6450\u20138.","journal-title":"Nucleic Acids Res"},{"key":"222_CR45","doi-asserted-by":"publisher","first-page":"1247997","DOI":"10.1126\/science.1247997","volume":"343","author":"M Jinek","year":"2014","unstructured":"Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014;343:1247997.","journal-title":"Science"},{"key":"222_CR46","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.1074\/jbc.M112.433094","volume":"288","author":"M Cheriyan","year":"2013","unstructured":"Cheriyan M, Pedamallu CS, Tori K, Perler F. Faster protein splicing with the Nostoc punctiforme DnaE intein using non-native extein residues. J Biol Chem. 2013;288:6202\u201311.","journal-title":"J Biol Chem"},{"key":"222_CR47","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1002\/anie.201102909","volume":"50","author":"NH Shah","year":"2011","unstructured":"Shah NH, Vila-Perello M, Muir TW. Kinetic control of one-pot trans-splicing reactions by using a wild-type and designed split intein. Angewandte Chemie. 2011;50:6511\u20135.","journal-title":"Angewandte Chemie"},{"key":"222_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","volume":"26","author":"A Moretti","year":"2020","unstructured":"Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med. 2020;26:207\u201314.","journal-title":"Nat Med"},{"key":"222_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210.","journal-title":"Orphanet J Rare Dis"},{"key":"222_CR50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83:529\u201336.","journal-title":"Neurology"},{"key":"222_CR51","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41591-019-0669-y","volume":"25","author":"AP Regensburger","year":"2019","unstructured":"Regensburger AP, Fonteyne LM, J\u00fcngert J, Wagner AL, Gerhalter T, Nagel AM, et al. Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy. Nat Med. 2019;25:1905\u201315.","journal-title":"Nat Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00222-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T07:07:07Z","timestamp":1632208027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00222-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00222-4","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}